← Back to News
Health Netherlands

Watchdog probes U.S. drugmaker Biogen over restricted access to multiple sclerosis test

NL Times ·
Watchdog probes U.S. drugmaker Biogen over restricted access to multiple sclerosis test
The ACM is probing Biogen for possibly abusing its market position by restricting access to a blood test for multiple sclerosis to only those using its medication, Tysabri. This investigation may impact pricing and patient options.

Summary

The Netherlands Authority for Consumers and Markets (ACM) is investigating U.S. drugmaker Biogen for potentially abusing its dominant market position in multiple sclerosis medication. The inquiry focuses on whether Biogen's restriction of a blood test to patients using its medication, Tysabri, constitutes unlawful tying practices. This could affect prices, availability, and patient choice in healthcare.

Read full article at NL Times ↗
#biogen#multiple_sclerosis#healthcare#acm#pharmaceuticals#patients#medication#investigation